Next Steps for Progressive Stem Cell Politics
By Marcy Darnovsky,
Science Progress
| 12. 16. 2008
The long-awaited stem cell announcement expected soon after inauguration day will be a welcome corrective to the Bush administration’s restrictions. As we anticipate a new policy—one that loosens federal funding for research using stem cell lines created with in vitro fertilization embryos not needed for reproductive purposes—let’s also take a good look at how to change the politics of stem cell research.
For the past eight years, the stem cell debate has been notable for its divisiveness. Controversy formed along the embryo divide; many liberals and progressives came to their positions in reaction to the Bush stem cell policy and the theological beliefs that helped motivate it.
In several election cycles, embryonic stem cell research became both hot potato and partisan wedge. Opponents persisted in absolutist rejection, while supporters countered with promises of imminent cures for diseases that, in a frequent hyperbolic refrain, “affect 128 million Americans.” The din of the stem cell war all but drowned out discussion of the non-embryo issues that stem cell research can pose.
But we should be able to conduct stem cell politics—and science...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...